Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
![The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]](/images/banners/nsclc.gif "The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]")
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Oestrogens / progestogens. |
| Generic Name : | Estradiol, dydrogesterone |
| Drug description : | Salmon-coloured, round, biconvex, film-coated tablets imprinted 'S' on one side and '379' on the other. |
| Presentation : | Tablets, estradiol (as hemihydrate) 1mg , dydrogesterone 5mg . |
| Indications : | Hormone replacement therapy (HRT) for the relief of menopausal symptoms in women with a uterus. Femoston-conti should normally be used only in women more than 12 months post-menopause. Prophylaxis of postmenopausal osteoporosis in women with a uterus at risk of developing fractures. |
| Adult Dosage : | One tablet daily. Tablets should be taken continuously without a break between packs. Refer to Summary of Product Characteristics. |
| Child Dosage : | Not recommended. |
| Contra Indications : | Active deep venous thrombosis within the last two years, thromboembolic disorders or a thromboembolic disorders or a history of confirmed thromboembolism (see Special Warnings and Precautions). Diagnosed, suspected, or past history of breast cancer, endometrial carcinoma or other hormone dependent neoplasia. Acute or chronic liver disease, and a history of liver disease where the liver function tests have failed to return to normal. Rotor syndrome or Dubin-Johnson syndrome. Cerebral vascular accident. Severe cardiac or renal disease. Undiagnosed vaginal bleeding. Known or suspected pregnancy. Lactation. Hypersensitivity to any of the components of the tablets. |
| Special Precautions : | A thorough examination is required before commencing therapy and at regular intervals thereafter. HRT is associated with an increased risk of venous thromboembolism (VTE). If risk factors present (personal or family history, severe obesity), weigh benefits against risks. An increased risk of being diagnosed with breast cancer has been reported with HRT. Monitor patients with otosclerosis, multiple sclerosis, systemic lupus erythematosus, porphyria, melanoma, epilepsy, migraine, asthma, haemoglobinopathies, diabetes mellitus, history of liver disease, uterine fibroids, history of endometriosis, hypertension, cardiac or renal dysfunction. Oestrogens can increase the risk of surgically confirmed gall bladder disease in women receiving postmenopausal oestrogens. Women of child bearing potential should use non- hormonal contraceptive methods. In the event of abnormal vaginal bleeding, a diagnostic endometrial biopsy should be performed. |
| Interactions : | Liver enzyme inducing drugs. |
| Adverse Reactions : | The following have been reported with oestrogen/progestogen therapy: breakthrough bleeding/ spotting, dysmenorrhoea, PMS, vaginal candidiasis, cervical changes, cystitis-like syndrome, breast tenderness/enlargement, nausea, vomiting, abdominal cramps/bloating, jaundice, skin reactions, eye changes, headache, migraine, dizziness, depression, chorea, changes in weight, carbohydrate metabolism or libido, oedema, porphyria and leg cramps. REASONS FOR IMMEDIATE DISCONTINUATION OF TREATMENT: Occurence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thromboembolism, or any other possible prodromal symptoms of vascular occlusion. Rise in blood pressure. Jaundice. Pregnancy. Discontinue six weeks before major elective surgery and during immobilisation entailing risk of thrombosis. |
| Manufacturer : | Solvay |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org